Charles River and Valence Discovery Announce Strategic Partnership to Provide Clients with AI-Enabled Drug Design Capabilities
Charles River Laboratories and Valence Discovery have formed a strategic partnership, enabling clients to utilize Valence's advanced AI platform for molecular property prediction, generative chemistry, and multiparameter optimization.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Charles River Laboratories International, Inc. (NYSE: CRL) and Valence Discovery today announced the formation of a strategic partnership to provide clients access to Valence’s artificial intelligence platform for molecular property prediction, generative chemistry, and multiparameter optimization.
This press release features mul